Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

2023/01/01 by April W. Armstrong, Melinda Gooderham, Richard B. Warren +13 · 1 citation

paper · doi:10.1016/j.jaad.2022.07.002

Cited by

• Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor